The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of and#8805;50%
Libtayo was superior in extending overall survival compared to chemotherapy even with a high crossover rate
Data are the basis for multiple ongoing regulatory submissions, including in the U.S. and European Union
TARRYTOWN, N.Y. and PARIS, Feb. 12, 2... Biopharmaceuticals, Oncology Regeneron Pharmaceuticals, Sanofi, Libtayo, cemiplimab, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals